MHRA Drug Safety Update: Botulinum toxin type A products
Cases of iatrogenic botulism have been reported following the therapeutic or cosmetic use of botulinum toxin containing products where the toxin’s effect extends beyond the area of treatment. Botulism caused by botulinum toxin is rare but can be life threatening. Symptoms can take up to four weeks to develop and may typically include difficulty breathing [...]
The post MHRA Drug Safety Update: Botulinum toxin type A products appeared first on Community Pharmacy England.
Recent Comments